Efficacy and safety of HRS ‐5965 monotherapy in complement inhibitor–naïve patients with paroxysmal nocturnal haemoglobinuria
British Journal of Haematology · 2025
DOI: 10.1111/bjh.20230 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Li Zhang und 7 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute …. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal, Complement Inactivating Agents. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Jiangsu Hengrui Pharmaceuticals, National High-Level Hospital Clinical Research Funding, Jiangsu Hengrui Medicine.
Abstract (Originalsprache)
Paroxysmal nocturnal haemoglobinuria (PNH) is a rare, life‐threatening disorder characterized by complement‐mediated haemolysis, leading to anaemia and thrombosis. HRS‐5965 is a novel, oral, selective complement factor B inhibitor targeting the alternative pathway, potentially reducing both intra‐ and extravascular haemolysis. In this randomized, open‐label phase II study, we evaluated the efficacy and safety of HRS‐5965 monotherapy in complement inhibitor–naïve adult PNH patients. Twenty‐six patients were randomized 1:1 to receive HRS‐5965 50 mg orally twice daily (BID) (with potential up‐titration to 100 mg BID) or 75 mg BID for 12 weeks. The primary end‐point was the change in haemoglobin (Hb) from baseline to Week 12. Both groups showed marked Hb increases, with least squares mean increases of 37.6 and 37.7 g/L for the 50 and 75 mg BID groups respectively. Lactate dehydrogenase levels declined by 87% and 85% from baseline. The most common treatment‐related adverse events were mild lab abnormalities, including increased alkaline phosphatase and alanine aminotransferase. In conclusion, HRS‐5965 monotherapy at either 50 or 75 mg BID resulted in substantial Hb improvements and reduced haemolysis with an acceptable safety profile, suggesting its potential as a promising oral therapy for complement inhibitor–naïve PNH patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical…
- Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, Beijing, China.
- Clinical Research and Development, Jiangsu Hengrui Pharmaceuticals Co Ltd, Shanghai, China.
Förderung
- Jiangsu Hengrui Pharmaceuticals
- National High-Level Hospital Clinical Research Funding
- Jiangsu Hengrui Medicine
Zitieren
APA
Zhang, L., Liu, Z., Zhao, X., Hu, B., Huang, R., Shu, C., Zhang, F., & Han, B. (2025). Efficacy and safety of HRS ‐5965 monotherapy in complement inhibitor–naïve patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. https://doi.org/10.1111/bjh.20230
Vancouver
Zhang L, Liu Z, Zhao X, Hu B, Huang R, Shu C, et al. Efficacy and safety of HRS ‐5965 monotherapy in complement inhibitor–naïve patients with paroxysmal nocturnal haemoglobinuria. British Journal of Haematology. 2025. doi:10.1111/bjh.20230
BibTeX
@article{Zhang2025,
author = {Zhang, Li and Liu, Ziwei and Zhao, Xin and Hu, Bin and Huang, Rong and Shu, Chang and Zhang, Fengkui and Han, Bing},
title = {Efficacy and safety of HRS ‐5965 monotherapy in complement inhibitor–naïve patients with paroxysmal nocturnal haemoglobinuria},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.20230}
}
EUVIMED